Competitive Technologies Reiterates Positive Forecast

May 02, 2005, 01:00 ET from Competitive Technologies, Inc.

    FAIRFIELD, Conn., May 2 /PRNewswire-FirstCall/ -- Competitive
 Technologies, Inc. (Amex:   CTT) announced today that it expects double-digit
 growth in fiscal 2005 revenue and net income over 2004 results. The CTT fiscal
 year ends July 31, 2005.
     "In response to the erroneous reporting by a financial website," said John
 B. Nano, CTT's President and CEO, "we felt it was important to reiterate CTT's
 strong revenue picture and its exciting portfolio of technologies.  As stated
 when we released record revenue and profit figures for the six months ended
 January 31, 2005, revenue will vary quarter to quarter.  We expect fiscal
 third quarter financials to continue us on our upward path, with resulting
 fiscal 2005 results to be substantially stronger showing double-digit growth
 in revenue and earnings over fiscal 2004.  CTT continues to leverage near-term
 opportunities while executing our longer-term strategies for sustained growth
 and increased shareholder value."
     Mr. Nano continued, "Our aggressive homocysteine assay-licensing program
 has been very successful.  In this quarter alone we have signed two major
 companies, Roche and Axis-Shield.  They join a group of CTT-licensed companies
 that include Bayer, Abbott, Quest and Diagnostic Products.  We believe
 CTT-licensed companies perform the majority of homocysteine assays in the
 marketplace.  A marketplace that is estimated at over 20 million homocysteine
 assays performed annually, with the number growing substantially each year.
 We expect millions of dollars of recurring revenue from our homocysteine assay
 technology in each of the fiscal years 2005, 2006 and 2007."
     Another important technology in the CTT portfolio is Video and Audio
 Signal Processing.  Two of CTT's encoding and compression technologies are
 included in the MPEG-4 Visual Patent Portfolio License Pool administered by
 MPEG LA.  The pool of 188 licenses includes Microsoft, Sony, Samsung, Apple,
 Canon, Cisco, General Instrument, Hitachi, LG Electronics, Toshiba,
 Matsushita, Mitsubishi, Fujitsu, Eastman Kodak and Sharp.  CTT is currently
 earning royalties from this rapidly growing pool as applications and licensees
     Exclusive licensee Palatin Technologies is developing CTT's male/female
 sexual dysfunction therapeutic in collaboration with King Pharmaceuticals.
 CTT's patented RFID "event-driven" information technology allows movement of
 individuals or assets to be tracked, coordinated and managed in applications
 including medical patient information, homeland security, military and general
 business.  The exclusive sub-licensee for CTT's sunless tanning technology,
 EpiTan Ltd., is researching the technology as a skin cancer preventative, and
 as a therapeutic for vitiligo, albinism and psoriasis.  CTT has exclusive
 rights to commercialize a patented injectible calcium phosphate-based
 nanotechnology bone biomaterial which can be used for human bones and for
 dental and veterinary uses.  Other technologies in CTT's dynamic portfolio
 include encryption technology, the EZSpeech(TM) software platform, an anti-
 cancer compound, plasma display panel energy recovery technology, and the
 Therapik(R) device.
     Mr. Nano further stated, "It is our view that our stock should trade
 higher than its current p/e ratio below 9.0 based on trailing four quarters of
 earnings per share of $1.08.  CTT has many valuable and innovative
 technologies in its portfolio.  A portfolio that continues to create revenue
 and profit growth for CTT's clients and shareholders."
     About Competitive Technologies, Inc.
     Competitive Technologies, established in 1968, is a full service
 technology transfer and licensing provider focused on the technology needs of
 its customers and transforming those requirements into commercially viable
 solutions.  CTT is a global leader in identifying, developing and
 commercializing innovative technologies in life, electronic, nano, and
 physical sciences developed by universities, companies and inventors.  The
 global market for technology transfer services is estimated at $150 billion
 annually.  CTT maximizes the value of intellectual assets for the benefit of
 its customers, clients and shareholders.  Visit CTT's website: .
     Statements about our future expectations, including development and
 regulatory plans, and all other statements in this document other than
 historical facts are "forward-looking statements" within the meaning of
 applicable Federal Securities Laws, and are not guarantees of future
 performance. These statements involve risks and uncertainties inherent in our
 business, including those set forth in Item 7 under the caption "Risk
 Factors," in our most recent Annual Report on Form 10-K filed with the SEC on
 October 29, 2004, and other factors that may be described in our other filings
 with the SEC, and are subject to change at any time.  Our actual results could
 differ materially from these forward-looking statements.  We undertake no
 obligation to update publicly any forward-looking statement.
      Direct inquiries to:  Johnnie D. Johnson, Strategic IR, Inc.
                            Tel. (212) 754-6565; Fax (212) 754-4333

SOURCE Competitive Technologies, Inc.